Brief: Alkem Labs Launches Neuceno (Cenobamate) For Treatment Of Partial-Onset Seizures In Adult Patients
16/09/2026 10:36
BRIEF-Alkem Labs Launches Neuceno (Cenobamate) For Treatment Of Partial-Onset Seizures In Adult Patients Sept 16 (Reuters) - Alkem Laboratories Ltd ALKE.NS:
ALKEM LABS- LAUNCHES NEUCENO (CENOBAMATE) FOR TREATMENT OF PARTIAL-ONSET SEIZURES IN ADULT PATIENTS
Source text: [ID:]
Further company coverage: ALKE.NS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alkem Laboratories
See all newsBrief: Alkem Labs Approved Initiation Of Forensic Audit In Connection With Recent Incident Involving Alleged Misappropriation Of Funds By A Former Employee
Brief: Alkem Labs Launches Neuceno (Cenobamate) For Treatment Of Partial-Onset Seizures In Adult Patients
Brief: Alkem Labs Launches Renocia Exo, Ginsenoside Exosome-Based Hair Growth Serum
Brief: Alkem Labs Board Approves Investment Of Up To 750 Million Rupees For New Block At Baddi Manufacturing Facility
Brief: Alkem Laboratories Q1 Consol Revenue From Operations 37.4 Billion Rupees